CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
D
Pipeline Grade
Financial Position (from SEC Filings)
$5.7M
Cash & Equivalents
$1.3M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$4M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-31 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06053242 | Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba... | PHASE2 | Recruiting | 45 |
| NCT05626712 | Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | PHASE2 | Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.